MNKD
NASDAQMannKind Corporation
News · 26 weeks71-50%
2026-03-012026-08-23
Mix2790d
- Other8(30%)
- Insider8(30%)
- SEC Filings6(22%)
- Earnings5(19%)
Latest news
25 items- SECSEC Form 8-K filed by MannKind Corporation8-K - MANNKIND CORP (0000899460) (Filer)
- SECSEC Form 424B7 filed by MannKind Corporation424B7 - MANNKIND CORP (0000899460) (Filer)
- INSIDERDirector Binder Steven B. sold $158,547 worth of shares (39,051 units at $4.06), decreasing direct ownership by 5% to 785,867 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- SECSEC Form 10-Q filed by MannKind Corporation10-Q - MANNKIND CORP (0000899460) (Filer)
- SECMannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MANNKIND CORP (0000899460) (Filer)
- PRMannKind Reports Second Quarter 2026 Financial Results and Provides Business UpdateAchieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza® following FDA approvalFUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKDPositive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement Encouraging early momentum in Afrezza pediatric launch 1 in 3 of the top 100 pediatric insulin writers have prescribed Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025Conference call and webcast today at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD)a biopharmaceutical company dedicated to tr
- PRMannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPFGenerally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in patients with IPFGlobal Phase 2 INFLO-2 trial actively enrolling patientsConference call and webcast scheduled for July 29 at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced positive topline results from INFLO-1, its Phase 1b randomized, double-blind, placebo-controlled study evaluating
- PRMannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026. MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update. The webcast of the conference call will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in the same location within 24 hours following the call and will be accessible for approximately 90 days. About MannKind MannK
- SECSEC Form 8-K filed by MannKind Corporation8-K - MANNKIND CORP (0000899460) (Filer)
- PRMannKind Announces $50 Million Private PlacementDANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors. The gross proceeds from the private placement financing are expected to be approximately $50 million. The closing of the financing is expected to occur on or about July 24, 2026, subject to the satisfaction of customary closing conditions. The private placement was l
- PRMannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney DiseaseTransformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital settingDelivers IV-equivalent diuretic effect through a simple, ready-to-use autoinjectorProvides an 80 mg/mL furosemide dose in a single administration in under 10 secondsSymptom relief may begin in an hour or lessConference call and webcast scheduled for July 24 at 9:00 a.m. ET WESTLAKE VILLAGE, Calif., and BOSTON, July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic an
- INSIDERChief Financial Officer Prentiss Christopher B covered exercise/tax liability with 22,247 shares, decreasing direct ownership by 7% to 318,668 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERPres, Endocrine Business Unit Marasco Dominic covered exercise/tax liability with 3,623 shares, decreasing direct ownership by 1% to 343,398 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief People & Workpl Officer Tross Stuart A converted options into 93,790 shares and covered exercise/tax liability with 65,808 shares, increasing direct ownership by 3% to 1,058,142 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief Executive Officer Castagna Michael converted options into 350,260 shares and covered exercise/tax liability with 363,200 shares, decreasing direct ownership by 0.53% to 2,433,779 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDEREVP Technical Operations Singh Sanjay R converted options into 70,550 shares and covered exercise/tax liability with 46,795 shares, increasing direct ownership by 5% to 478,966 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDEREVP Genl Counsel & Secretary Thomson David covered exercise/tax liability with 98,426 shares, sold $97,641 worth of shares (24,109 units at $4.05) and converted options into 93,790 shares, decreasing direct ownership by 3% to 797,554 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERDirector Binder Steven B. sold $213,089 worth of shares (52,485 units at $4.06), converted options into 93,790 shares and covered exercise/tax liability with 24,395 shares, increasing direct ownership by 2% to 824,918 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- PRMannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1DCollaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced it has been awarded a grant from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes (T1D) research and advocacy organization, through its Industry Discovery and Development Partnership (IDDP) program, to support the ongoing INHALE-1ST clinical study evaluati
- PRData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) SystemsBuilds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfactionExploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithmsData from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic dis
- PRMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFPhase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and support its progression into mid-stage clinica
- SECMannKind Corporation filed SEC Form 8-K: Other Events8-K - MANNKIND CORP (0000899460) (Filer)
- PRMannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalDANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions
- PRMannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with DiabetesEnables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association (ADA) Standards of Care alongside multiple daily injections (MDI) and insulin pumpsApproval is supported by results from the Phase 3 INHALE-1 study in pediatric patients, along with clinical efficacy and safety evidence generated across thousands of patients over the past 20+ years of Technosphere® inhaled insulin developmentEligible patients can access Afrezza today for $35 or less per month, with
- SECMannKind Corporation filed SEC Form 8-K: Other Events8-K - MANNKIND CORP (0000899460) (Filer)
MNKD FAQ
7 questionsWhat does MannKind Corporation do?
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary...Where does MNKD stock trade?
MannKind Corporation (MNKD) is listed on NASDAQ.What sector and industry is MNKD in?
MannKind Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MannKind Corporation go public?
MannKind Corporation (MNKD) completed its IPO in 2004.What are analysts saying about MNKD?
MannKind Corporation has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform with a $350.00 price target on 2026-02-27. Recent price targets range from $350.00 to $1200.00.What companies are similar to MNKD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MNKD side-by-side with any of them on Quantisnow.How can I track MNKD on Quantisnow?
Quantisnow aggregates MannKind Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNKD to receive live email and push alerts on every new disclosure.